- Home
- NRXS vs IMNN Comparison
NRXS vs IMNN Comparison
Compare NRXS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- IMNN
- Stock Information
- Founded
- NRXS 2011
- IMNN 1982
- Country
- NRXS United States
- IMNN United States
- Employees
- NRXS N/A
- IMNN N/A
- Industry
- NRXS
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- IMNN Health Care
- Exchange
- NRXS Nasdaq
- IMNN Nasdaq
- Market Cap
- NRXS 13.0M
- IMNN 12.1M
- IPO Year
- NRXS 2023
- IMNN 1985
- Fundamental
- Price
- NRXS $2.60
- IMNN $1.40
- Analyst Decision
- NRXS
- IMNN Buy
- Analyst Count
- NRXS 0
- IMNN 2
- Target Price
- NRXS N/A
- IMNN $14.00
- AVG Volume (30 Days)
- NRXS 4.9M
- IMNN 31.3M
- Earning Date
- NRXS 05-12-2025
- IMNN 05-12-2025
- Dividend Yield
- NRXS N/A
- IMNN N/A
- EPS Growth
- NRXS N/A
- IMNN N/A
- EPS
- NRXS N/A
- IMNN N/A
- Revenue
- NRXS $2,934,945.00
- IMNN N/A
- Revenue This Year
- NRXS $138,883.78
- IMNN N/A
- Revenue Next Year
- NRXS $118.59
- IMNN N/A
- P/E Ratio
- NRXS N/A
- IMNN N/A
- Revenue Growth
- NRXS 27.52
- IMNN N/A
- 52 Week Low
- NRXS $1.33
- IMNN $0.37
- 52 Week High
- NRXS $6.20
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- NRXS 50.26
- IMNN 51.86
- Support Level
- NRXS $2.59
- IMNN $0.85
- Resistance Level
- NRXS $2.82
- IMNN $3.16
- Average True Range (ATR)
- NRXS 0.46
- IMNN 0.51
- MACD
- NRXS -0.04
- IMNN 0.07
- Stochastic Oscillator
- NRXS 12.83
- IMNN 36.92
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).